Integra LifeSciences (NASDAQ:IART) Reaches New 52-Week Low – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares reached a new 52-week low on Wednesday . The company traded as low as $8.88 and last traded at $8.7990, with a volume of 30116 shares traded. The stock had previously closed at $9.10.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IART. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Wells Fargo & Company dropped their price target on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, February 27th. Citigroup cut their price target on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a research note on Wednesday, March 11th. Finally, Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $14.40.

Integra LifeSciences Trading Down 2.8%

The firm has a market cap of $689.35 million, a price-to-earnings ratio of -1.31 and a beta of 1.02. The business has a 50 day moving average of $11.27 and a 200 day moving average of $12.78. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. During the same quarter in the previous year, the company posted $0.97 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Several hedge funds and other institutional investors have recently bought and sold shares of IART. Global Retirement Partners LLC acquired a new position in Integra LifeSciences in the 4th quarter valued at $25,000. GAMMA Investing LLC grew its position in shares of Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 913 shares during the period. Osaic Holdings Inc. grew its position in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the period. EMC Capital Management acquired a new position in Integra LifeSciences in the second quarter valued at $75,000. Finally, Tower Research Capital LLC TRC lifted its position in Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after buying an additional 6,814 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.